A recent study in breast cancer patient samples and cell lines revealed that the elevated expression of factors that promote chromatin accessibility and gene expression, such as COMPASS, BAF, KDM4B, and KAT6B, leads to increased sensitivity to anthracycline treatment, whereas factors that promote chromatin compaction, such as PRC2, lead to anthracycline resistance (80). This evidence concerns the gene KAT6B and breast cancer.